Hints and tips:
...As well as proceeds from its Covid products, Pfizer has also benefited from the spin-off of its Upjohn generics business, which combined with Mylan to form Viatris in late 2020....
...The Swiss pharmaceuticals group is following many rivals to focus its operations on higher-value innovative treatments rather than the cheaper off-patent drugs made by Sandoz, including generic versions...
...Gilead told the FT that in India the price of the drug and the terms of supply are negotiated by the US company Viatris, previously also known as Mylan, which holds the marketing authorisation for AmBisome...
...Results and forecasts exclude its Upjohn unit, as Pfizer closed the transaction to merge the generics business with Mylan during the quarter....
...Mylan, which makes a generic version of Truvada, pays royalties for some its sales to the CDC. When the generic market forms in the US, it said, it will continue to do so....
...Mylan, a US-based generics maker, has restarted production of hydroxychloroquine at its West Virginia plant and is looking to increase manufacturing outside of the US too....
...In mid-afternoon trading in New York, shares in Mylan, which is in the process of merging with Pfizer’s generics business Upjohn, were up 2.6 per cent to $22.83....
...Teva, Mylan and others in the lawsuits have denied wrongdoing....
...The deal with Mylan is similar. Here, however, Pfizer is spinning off Upjohn and then combining it with all of Mylan....
...Merck is the latest pharmaceutical company to try to streamline its business to focus on higher-growth — and usually higher-priced — drugs....
...Last quarter, the company said sales of its multiple sclerosis drug were worse than expected, and it failed to received approval to make a generic version of Advair, an asthma medicine developed by UK pharmaceutical...
...Pfizer has reached a deal to spin off its Upjohn unit and combine it with generics drugmaker Mylan to create an off-patent pharmaceutical group with an enterprise valuation of about $50bn....
..., for $63bn; Pfizer’s sale of its off-patent drug business to Mylan for $9.5bn; and Roche’s $4.8bn takeover of gene therapy company Spark Therapeutics....
...Rivals entering the market include Amgen, Sandoz, Biogen, Samsung Bioepis and Mylan. In the first quarter, Humira represented 56 per cent of revenue at $4.4bn....
...Mylan does not make the EpiPens itself. It gave the job to Pfizer, the US pharmaceutical company, which it seems messed it up....
...patent that for 15 years has protected Humira, the world’s best-selling prescription drug, from generic competition expires in Europe — triggering a tussle among a string of the most prominent names in the pharmaceuticals...
...Amgen, Sandoz, Mylan, and Samsung Bioepis launched copycat drugs in Europe two weeks ago. Prices differ between markets but are between 10 and 80 per cent cheaper....
...A rival allergy injector known as Adrenaclick, which is marketed by Amneal Pharmaceuticals, is also in short supply because of issues at a Pfizer plant in McPherson, Kansas, which makes the crucial ingredient...
...Chrys Kokino, global biologics head for US drugmaker Mylan, which has seen prices for its generic drugs squeezed in recent years, said his own company was “very heavily invested [in] and committed to the...
...The companies now under investigation are: Heritage Pharmaceuticals, Inc.; Aurobindo Pharma USA, Inc.; Citron Pharma, LLC; Mayne Pharma (USA), Inc.; Mylan Pharmaceuticals, Inc.; Teva Pharmaceuticals USA;...
...It is one of the world’s most recognised pharmaceuticals brands, but Botox — the wrinkle treatment beloved by celebrities and more — is starting to show signs of age....
...October struck down a patent protecting its second-best seller, Restasis — a prescription eye drop, which generated roughly $1.5bn in sales for Allergan in 2016 — and flung open the doors to competitors like Mylan...
...The Texas judge said the intellectual property was invalid, opening the way for generic competitors Mylan and Teva to market a cheaper copycat version of the prescription eye drop Restasis....
...The most high-profile recent mis-step was a big bet on drugmaker Valeant Pharmaceuticals....
...Its p/e is also much higher than that of its overseas rivals such as Biocon of India and Mylan of the US....
International Edition